布地奈德联合沙美特罗治疗哮喘患儿的效果  

Effect of Budesonide Combined With Salmeterol in the Treatment of Children With Asthma

作　　者：谢欢欢 邓镜业[2] XIE Huanhuan;DENG Jingye(Department of General Medicine,Jiangmen Second People’s Hospital,Jiangmen Guangdong 529000,China;Department of Pediatrics,Jiangmen Central Hospital,Jiangmen Guangdong 529000,China)

机构地区：[1]江门市第二人民医院全科,广东江门529000 [2]江门市中心医院儿内科,广东江门529000

出　　处：《中国卫生标准管理》2021年第13期112-115,共4页China Health Standard Management

摘　　要：目的探讨布地奈德联合沙美特罗治疗哮喘患儿的效果。方法选2019年9月—2020年9月于医院治疗的哮喘患儿72例,随机分为两组。对照组应用布地奈德,研究组在此基础上应用沙美特罗,观察比对两组治疗前后的白细胞介素-10(interleukin-10,IL-10)、CRC反应蛋白(CRC reactive protein,CRP)、白细胞介素-4(interleukin-4,IL-4)、丙二醛(malondialdehyde,MDA)、血清还原型谷胱甘肽(serum reduced glutathione,GSH)、超氧化歧化酶(superoxide dismutase,SOD)、第一秒呼气容积(first second expiratory volume1,FEV_(1))、呼气流量峰值(peak expiratory flow,PEF)以及一秒率(FEV_(1)/FVC)。结果研究组治疗后IL-10(14.75±1.81)ng/L高于对照组(10.25±1.55)ng/L,CRP(6.21±0.85)mg/L、IL-4(8.25±1.39)ng/L低于对照组(8.85±1.11)mg/L、(12.25±1.74)ng/L(P<0.05);研究组治疗后GSH(75.70±9.53)mg/mL、SOD(40.11±4.85)U/L高于对照组(63.68±8.89)mg/mL、(33.60±4.28)U/L,MDA(13.47±0.93)mmol/L低于对照组(18.61±1.56)mmol/L(P<0.05);研究组治疗后PEF(3.43±0.38)L/s、FEV_(1)/FVC(84.10±5.02)%、FEV_(1)(2.31±0.39)L高于对照组(2.91±0.34)mL/s、(74.96±9.74)%、(1.95±0.33)L(P<0.05)。结论哮喘患儿应用沙美特罗+布地奈德治疗效果较好,可以有效改善机体中的炎性水平和氧化应激反应,从而提高治疗效果,改善患儿的肺功能。Objective To investigate the effect of budesonide combined with salmeterol on clinical efficacy in children with asthma.Methods A total of 72 children with asthma who were treated in our hospital from September 2019 to September 2020 were selected and randomly divided into two groups.The control group was treated with budesonide,and the study group was treated with salmeterol on this basis to observe and compare the interleukin-10(IL-10),CRC reactive protein(CRP)and interleukin-4(IL-4),malondialdehyde(MDA),serum reduced glutathione(GSH),superoxide dismutase(SOD),first second expiratory volume(FEV_(1)),peak expiratory flow(PEF),and FEV_(1)/FVC.Results After treatment,IL-10 in the study group(14.75±1.81)ng/L was higher than that in the control group(10.25±1.55)ng/L,CRP(6.21±0.85)mg/L and IL-4(8.25±1.39)ng/L were lower than that in the control group(8.85±1.11)mg/L and IL-4(12.25±1.74)ng/L(P<0.05).After treatment,GSH(75.70±9.53)mg/mL and SOD(40.11±4.85)U/L in the study group were higher than those in the control group(63.68±8.89)mg/mL and(33.60±4.28)U/L,MDA(13.47±0.93)mmol/L were lower than those in the control group(18.61±1.56)mmol/L(P<0.05).After treatment,PEF(3.43±0.38)L/s,FEV_(1)/FVC(84.10±5.02)%,FEV_(1)(2.31±0.39)Lin the study group were higher than those in the control group(2.91±0.34)mL/s,(74.96±9.74)%and(1.95±0.33)L(P<0.05).Conclusion Salmeterol combined with budesonide is effective in the treatment of children with asthma,which can effectively improve the inflammatory level and oxidative stress response in the body,so as to improve the treatment effect and improve the lung function of children.

关 键 词：布地奈德 沙美特罗 哮喘患儿 治疗效果 血清CRP IL-4 IL-10 

分 类 号：R562[医药卫生—呼吸系统]